72 results about "Clinical correlation" patented technology

The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression.

A computer-based system and method are provided for retrieving information from a number of data sources on a computer network containing biological data. The network database is organized in a b-tree configuration having a plurality of sample nodes. Each sample node includes a curated data set of pre-formatted and pre-computed summary biological data obtained from at least one biological sample. The plurality of sample nodes are organized in a hierarchical arrangement according to clinical relevance. A set of attributes is assigned to each sample node to facilitate navigation through the database using a browser accessible through a graphical user interface. The set of attributes including at least one taxonomy designation selected from the group including tissues, diseases, medications and sample parameters. Search results that are produced include automated reports of the summary biological data stored in the sample nodes and custom reports generated using the summary biological data.

The invention relates to the identification and use of gene expression profiles with clinical relevance to the treatment of cellular proliferative disorders, especially those mediated by aberrant Notch signaling using a Notch signaling inhibitor. In particular, the invention provides the identities of genes, whose individual or cumulative expression patterns may be useful in various assays. The gene expression profiles, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to select subjects afflicted with a Notch mediated cancer who will likely respond to treatment with a gamma-secretase inhibitor or another Notch inhibiting agent. The same markers may be used in the classification of patients being treated with other Notch inhibitors. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. The methods may further comprise selecting a treatment based on the classifying step.

A method and system for assessing alarm events generated in a physiological monitoring system is described. The method identifies one or more qualitative measures associated with the generation of the alarm event. The one or more qualitative measures can include a calculated trajectory of the monitored physiological parameter, the calculated time between alarm events and the duration of the current alarm event. Based upon the qualitative measures, the method calculates a clinical relevancy score for the alarm event. The alarm event, each of the qualitative measures and the clinical relevancy score are presented on a display panel. The method and system can generate an urgent alarm based on the calculated relevancy score. The system includes a processor that calculates the clinical relevancy score based on qualitative measures and algorithms entered into the processor.

This invention is a model that simulates the complexity of biological signaling in a cell in response to radiation therapy. Using gene expression profiles and radiation survival assays in an algorithm, a systems model was generated of the radiosensitivity network. The network consists of ten highly interconnected genetic hubs with significant signal redundancy. The model was validated with in vitro tests perturbing network components, correctly predicting radiation sensitivity 2/3 times. The model's clinical relevance was shown by linking clinical radiosensitivity targets to the model network. Clinical applications were confirmed by testing model predictions against clinical response to preoperative radiochemotherapy in patients with rectal or esophageal cancer.

The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens.

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens.

The invention provides a unicell detection method for a tumor sample by means of a mass spectrum flow system. The method comprises the following steps that (1) a cancer tissue biopsy sample or blood sample of a tumor patient is collected and processed to prepare a unicell suspension; (2) an antibody labeled with metal elements is used to mark the suspended unicell suspension with multiple targetsat the same time; (3) the marked unicell sample is detected by the mass spectrum flow system; and (4) on the basis of obtained mass spectrum flow type detection data, different immunocyte subgroups are clustered and analyzed, and expression levels of protein in tumor immunization detection points in different subgroup cells are quantitatively analyzed. Thus, the immucyte subgroups that can reflectthe clinical response degree of tumor immunotherapy can be accurately found in the immunocyte cells related to tumor of high heteroplasmy, the protein expression level threshold of the tumour immunization detection pointd can be determined appropriately, and a detection result is high in clinical correlation. Thus, the method has good clinical application prospects and higher social benefit.

The invention discloses a kit for detecting total bilirubin by using a vanadate oxidation method. The kit consists of a reagent 1 and a reagent 2 in the mixture ratio of 3:1. In the invention, by adding a compound, the solubility of vanadic acid is increased and cannot be reduced under the acid condition, thereby accelerating the reaction of the total bilirubin. In addition, an anti-interference substance is added in the kit to improve the capability of resisting an ascorbic acid interference reaction in a reaction process, so that the test result and a diazonium salt method have favorable clinical correlation. The kit has a better clinical application prospect.

The invention relates to a demonstration model for simulating the pathological change of acute glomerulonephritis. The invention belongs to a medical teaching device, and particularly relates to a teaching aid for demonstrating the pathological change of acute glomerulonephritis. The teaching aid mainly comprises a heart model, an afferent glomerular arteriole model, a glomerular capillary u-shaped loop model, a mesangial region saccus model, an efferent glomerular arteriole model, a renal capsule model, a renal tubule model, a urine pool and a blood pool, thereby forming a model system for demonstrating the pathological clinical correlation of acute glomerulonephritis. The device is simple in structure and convenient to operate, and has high visuality and understandability in the teaching process. Besides, the device facilitates students to foster the observation and problem analysis capabilities.

The invention belongs to the technical field of polygene detection of gastric cancer, and discloses a gastric cancer detection panel based on a next-generation sequencing technology. According to theinvention, important exon regions and a part of intron regions of 557 genes are enriched by using a gene probe hybridization method, and high-depth sequencing is carried out, so events such as gene mutation, copy number variation and the like having clear clinical correlation with the gastric cancer can be accurately detected; and a multi-gene screening list is made into a probe, and high-risk genes are detected in a targeted mode through DNA sequencing, so gene mutation with guiding significance for diagnosis and treatment can be detected more efficiently, accurate typing of tumor patients are realized, and meanwhile, a plurality of tumor patients can be helped to participate in clinical tests.

The present invention relates to mixed esters of hyaluronic acid, wherein the hydroxyl groups are partially esterified with retinoic and butyric acids. These mixed esters are characterized by specific degrees of esterification and by a high ratio between the degree of substitution with butyric acid and retinoic acid. They exhibit a high anti-proliferative activity associated with activation of cell differentiation, with consequent clinical relevance in the treatment of hyper-proliferative pathologies and in particular of solid and systemic tumors.

The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis (OA). In particular, the invention provides the identity of marker proteins whose expression is correlated with OA and OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.

The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis (OA). In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, OA subtype, and/or OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.

The invention describes for the first time the preclinical/cellular and clinical relevance of VIP, PACAP as well as of substances with the same biological activity as VIP and PACAP for the treatment of interstitial lung infections such as idiopathic pulmonary fibrosis, hypersensitive pneumonia or diffused panbronchiolitis. VIP and PACAP are synthesised in different areas of the central nervous system, e.g. in specific cerebral areas such as the hippocampus and the cortex, as well as in the peripheral ganglia. VIP is also released by immune cells.

A medical device and method for detection, retrieval or elimination of disease-associated toxins and biomarkers is provided. A plurality of magnets is arranged within a flexible sheath forming a flexible wire. The magnets are magnetically attached to each other, end-to-end, and arranged with their magnetic polarities alternating in direction. The magnetization direction of each of the magnets is orthogonal to the length axis of the flexible wire. The medical device is completely self-contained and does not require a bulky external field source able to maintain strong magnetic field gradients (100-10,000 T/m) along the wire, and at a radial distance (˜1 mm) to attract magnetic particles throughout the entire vein diameter at a range of physiologic velocities (1-10 cm/sec). This technology is a major step forward for the clinical relevance of CTC analysis to personalized medicine and introduces a powerful generalizable strategy for enrichment of other rare blood biomarkers.

The invention belongs to the technical field of liver cancer polygene detection, and discloses a liver cancer detection panel based on a next-generation sequencing technology. Important exon regions and partial intron regions of 557 genes are enriched by using a gene probe hybridization method, and high-depth sequencing is carried out, so that events such as gene mutation and copy number variation which have clear clinical correlation with liver cancer are accurately detected; and a polygene screening list is made into a probe, and high-risk genes are detected in a targeted mode through DNA sequencing, so that gene mutation with guiding significance for diagnosis and treatment can be detected more efficiently, and important guiding significance is achieved for clinical diagnosis and discovery of targets of targeted therapy.

The invention discloses a differential proteomic analysis method using transcriptome sequencing and based on combination of iTRAQ and LC-MALDI. The method comprises the steps: (1) transcriptome sequencing is performed; (2) differential proteomic analysis is used for extracting the total protein fluid of livers of normal group rats and liver cancer group rats, the two groups are mixed respectively,proteins are precipitated and quantified by an acetone precipitation method, each group contains about 100 [mu]g of the total proteins, trypsin enzymolysis, reduction alkylation, iTRAQ labeling and the like are performed successively, and the process is performed by strictly following instructions of an iTRAQ kit; and (3) bioinformatics analysis is performed. A clinical sample is adopted for positioning and quantitative expression verification, an evidence of the clinical sample with clinical relevance is searched, clinical value is evaluated, and a new clue is provided for research of livercancer pathogenesis and a liver cancer mechanism. Liver cancer key molecules screened by the project can lay the research basis for exploration of liver cancer markers related to early detection, classification and prognosis evaluation, and selection of more effective and accurate liver cancer treatment target positions.